EU Demands Pfizer Offload Its Infliximab Biosimilar In Hospira Buy
This article was originally published in The Pink Sheet Daily
Pfizer won EU antitrust approval for its plan to buy Hospira after promising to divest certain assets including its own biosimilar version of tumor necrosis factor inhibitor infliximab, to allay competition concerns. Still open are questions about possible buyers and what this means for competitors.
You may also be interested in...
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.